{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,21]],"date-time":"2025-12-21T10:24:15Z","timestamp":1766312655465,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T00:00:00Z","timestamp":1546905600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s12072-018-9922-6","type":"journal-article","created":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T21:55:32Z","timestamp":1546984532000},"page":"214-221","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Mutations in CYP2C9 and\/or VKORC1 haplotype are associated with higher bleeding complications in patients with Budd\u2013Chiari syndrome on warfarin"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7718-9452","authenticated-orcid":false,"given":"Akash","family":"Shukla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhinav","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinit","family":"Kahalekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheetal","family":"Bendkhale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nithya","family":"Gogtay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Urmila","family":"Thatte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shobna","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,8]]},"reference":[{"key":"9922_CR1","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.1478-3231.2008.01684.x","volume":"28","author":"JD Horton","year":"2008","unstructured":"Horton JD, San Miguel FL, Membreno F, et al. Budd\u2013Chiari syndrome: illustrated review of current management. Liver Int. 2008;28:455\u201366.","journal-title":"Liver Int"},{"issue":"e1\u2013319","key":"9922_CR2","first-page":"e6","volume":"38","author":"C Zhang","year":"2017","unstructured":"Zhang C, Gu V, Zhu G, Luo T, Yan C, Wang Z. Hybrid treatment for Budd\u2013Chiari syndrome\u2014a case report by 11-year follow up. Ann Vasc Surg. 2017;38(e1\u2013319):e6.","journal-title":"Ann Vasc Surg"},{"key":"9922_CR3","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jhep.2008.10.007","volume":"50","author":"DC Valla","year":"2009","unstructured":"Valla DC. Primary Budd\u2013Chiari syndrome. J Hepatol. 2009;50:195\u2013203.","journal-title":"J Hepatol"},{"key":"9922_CR4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1097\/00042737-200501000-00007","volume":"17","author":"V Bogin","year":"2005","unstructured":"Bogin V, Marcos A, Shaw-Stiffel T. Budd\u2013Chiari syndrome: in evolution. Eur J Gastroenterol Hepatol. 2005;17:33\u20135.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"9922_CR5","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/sj.clpt.6100290","volume":"83","author":"NA Limdi","year":"2008","unstructured":"Limdi NA, McGwin G, Goldstein JA, et al. Influence of CYP2C9 and VKORC1 1173C\/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther. 2008;83:312\u201321.","journal-title":"Clin Pharmacol Ther"},{"key":"9922_CR6","doi-asserted-by":"publisher","first-page":"e44064","DOI":"10.1371\/journal.pone.0044064","volume":"7","author":"AL Jorgensen","year":"2012","unstructured":"Jorgensen AL, FitzGerald RJ, Oyee J, Pirmohamed M, Williamson PR. Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis. PLoS One. 2012;7:e44064.","journal-title":"PLoS One"},{"key":"9922_CR7","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.jacc.2010.08.643","volume":"57","author":"BS Finkelman","year":"2011","unstructured":"Finkelman BS, Gage BF, Johnson JA, Brensinger CM, Kimmel SE. Genetic warfarin dosing: tables versus algorithms. J Am Coll Cardiol. 2011;57:612\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"9922_CR8","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/clpt.2008.10","volume":"84","author":"BF Gage","year":"2008","unstructured":"Gage BF, Eby C, Johnson JA, Deych E, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther. 2008;84:326\u201331.","journal-title":"Clin Pharmacol Ther"},{"key":"9922_CR9","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa0809329","volume":"360","author":"TE Klein","year":"2009","unstructured":"International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB, Eriksson N, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009;360:753\u201364.","journal-title":"N Engl J Med"},{"key":"9922_CR10","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1055\/s-0028-1085094","volume":"28","author":"A Plessier","year":"2008","unstructured":"Plessier A, Valla DC. Budd\u2013Chiari syndrome. Semin Liver Dis. 2008;28:259\u201369.","journal-title":"Semin Liver Dis"},{"key":"9922_CR11","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1111\/j.1365-2036.2009.04134.x","volume":"30","author":"AJ Montano-Loza","year":"2009","unstructured":"Montano-Loza AJ, Tandon P, Kneteman N, Baily R, Bain VG. Rotterdam score predicts early mortality in Budd\u2013Chiari syndrome, and surgical shunting prolongs transplant free survival. Aliment Pharmacol Ther. 2009;30:1060\u20139.","journal-title":"Aliment Pharmacol Ther"},{"key":"9922_CR12","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1053\/he.2000.5852","volume":"31","author":"M Malinchoc","year":"2000","unstructured":"Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000;31:864\u201371.","journal-title":"Hepatology"},{"key":"9922_CR13","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/GIM.0b013e318163c35f","volume":"10","author":"DA Flockhart","year":"2008","unstructured":"Flockhart DA, O\u2019Kane D, Williams MS, ACMG Working Group on Pharmacogenetic Testing of CYP2C9, VKORC1 Alleles for Warfarin Use, et al. Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med. 2008;10:139\u201350.","journal-title":"Genet Med"},{"key":"9922_CR14","unstructured":"COUMADIN-Warfarin Sodium Tablet) [package insert]. Princeton: Bristol-Myers Squibb Pharma Company; 2015. Available from: \n                    http:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=d91934a0-902e-c26c-23ca-d5accc4151b6\n                    \n                  . Accessed 20 Apr 2018."},{"issue":"1","key":"9922_CR15","doi-asserted-by":"publisher","first-page":"62","DOI":"10.2174\/1574884711666160118095322","volume":"11","author":"K Sridharan","year":"2016","unstructured":"Sridharan K, Modi T, Bendkhale S, Kulkarni D, Gogtay NJ, Thatte UM. Association of genetic polymorphisms of CYP2C9 and VKORC1 with bleeding following warfarin: a case-control study. Curr Clin Pharmacol. 2016;11(1):62\u20138.","journal-title":"Curr Clin Pharmacol"},{"issue":"3","key":"9922_CR16","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","volume":"63","author":"R Franchis De","year":"2015","unstructured":"De Franchis R, Baveno VI faculty. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63(3):743\u201352.","journal-title":"J Hepatol"},{"key":"9922_CR17","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692\u20134.","journal-title":"J Thromb Haemost"},{"issue":"2","key":"9922_CR18","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s11239-015-1305-4","volume":"41","author":"P Sand\u00e9n","year":"2016","unstructured":"Sand\u00e9n P, Renlund H, Svensson PJ, Sj\u00e4lander A. Bleeding complications in venous thrombosis patients on well-managed warfarin. J Thromb Thrombolysis. 2016;41(2):351\u20138.","journal-title":"J Thromb Thrombolysis"},{"key":"9922_CR19","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.cgh.2012.01.012","volume":"10","author":"MG Delga do","year":"2012","unstructured":"do Delga MG, Seijo S, Yepes I, et al. Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis1. Clin Gastroenterol Hepatol. 2012;10:776\u201383.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"9922_CR20","doi-asserted-by":"publisher","first-page":"167","DOI":"10.7326\/0003-4819-151-3-200908040-00004","volume":"151","author":"MS Darwish","year":"2009","unstructured":"Darwish MS, Plessier A, Hernandez-Guerra M, et al. Etiology, management, and outcome of the Budd\u2013Chiari syndrome. Ann Intern Med. 2009;151:167\u201375.","journal-title":"Ann Intern Med."},{"key":"9922_CR21","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1002\/hep.26306","volume":"57","author":"S Seijo","year":"2013","unstructured":"Seijo S, Plessier A, Hoekstra J, et al. Good long term outcome of Budd\u2013Chiari syndrome with a step-wise management. Hepatology. 2013;57:1962\u20138.","journal-title":"Hepatology"},{"issue":"1","key":"9922_CR22","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s12664-010-8002-1","volume":"29","author":"A Shukla","year":"2010","unstructured":"Shukla A, Bhatia SJ. Outcome of patients with primary hepatic venous obstruction treated with anticoagulants alone. Indian J Gastroenterol. 2010;29(1):8\u201311.","journal-title":"Indian J Gastroenterol"},{"issue":"2","key":"9922_CR23","doi-asserted-by":"publisher","first-page":"e134","DOI":"10.1016\/j.thromres.2010.03.015","volume":"126","author":"E Pasmant","year":"2010","unstructured":"Pasmant E, de Beauvoir C, Plessier A, Labreuche J, Bezeaud A. VKORC1 and CYP2C9 genetic polymorphisms in hepatic or portal vein thrombosis. Thromb Res. 2010;126(2):e134\u20136.","journal-title":"Thromb Res"},{"issue":"124","key":"9922_CR24","first-page":"2030","volume":"3","author":"PR Benusiglio","year":"2007","unstructured":"Benusiglio PR, Desmeules J, de Moerloose P, Dayer P. Oral anticoagulation and pharmacogenetics: importance in the clinical setting. Rev Med Suisse. 2007;3(124):2030 (2033-4, 2036).","journal-title":"Rev Med Suisse"},{"key":"9922_CR25","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s00228-003-0666-3","volume":"59","author":"C Adithan","year":"2003","unstructured":"Adithan C, Gerard N, Vasu S, Balakrishnan R, Shashindran CH, Krishnamoorthy R. Allele and genotype frequency of CYP2C9 in Tamilnadu population. Eur J Clin Pharmacol. 2003;59:707\u20139.","journal-title":"Eur J Clin Pharmacol"},{"key":"9922_CR26","first-page":"34","volume":"60","author":"K Shalia","year":"2012","unstructured":"Shalia K, Doshi SM, Parikh S, et al. Prevalence of VKORC1 and CYP2C9 gene polymorphisms in Indian population and its effect on warfarin response. JAPI. 2012;60:34\u20138.","journal-title":"JAPI"},{"issue":"24","key":"9922_CR27","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1056\/NEJMoa1311386","volume":"369","author":"M Pirmohamed","year":"2013","unstructured":"Pirmohamed M, Burnside G, Eriksson N, EU-PACT Group, et al. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med. 2013;369(24):2294\u2013303.","journal-title":"N Engl J Med"},{"issue":"24","key":"9922_CR28","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1056\/NEJMoa1310669","volume":"369","author":"SE Kimmel","year":"2013","unstructured":"Kimmel SE, French B, Kasner SE, COAG Investigators, et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med. 2013;369(24):2283\u201393.","journal-title":"N Engl J Med"},{"issue":"3","key":"9922_CR29","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/cpt.668","volume":"102","author":"JA Johnson","year":"2017","unstructured":"Johnson JA, Caudle KE, Gong L, et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update. Clin Pharmacol Ther. 2017;102(3):397\u2013404.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"9922_CR30","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1056\/NEJMra1011170","volume":"365","author":"A Tripodi","year":"2011","unstructured":"Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med. 2011;365(2):147\u201356.","journal-title":"N Engl J Med"},{"key":"9922_CR31","doi-asserted-by":"publisher","first-page":"967","DOI":"10.2147\/TCRM.S84210","volume":"11","author":"YH Mekaj","year":"2015","unstructured":"Mekaj YH, Mekaj AY, Duci SB, Miftari EI. New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag. 2015;11:967\u201377.","journal-title":"Ther Clin Risk Manag"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-018-9922-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12072-018-9922-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-018-9922-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T19:24:07Z","timestamp":1578425047000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12072-018-9922-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,8]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["9922"],"URL":"https:\/\/doi.org\/10.1007\/s12072-018-9922-6","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"type":"print","value":"1936-0533"},{"type":"electronic","value":"1936-0541"}],"subject":[],"published":{"date-parts":[[2019,1,8]]},"assertion":[{"value":"29 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical requirements"}},{"value":"Akash Shukla, Abhinav Jain, Vinit Kahalekar, Shital Bendkhale, Nithya Gogtay, Urmila Thatte and Shobna Bhatia have no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008 (5). Informed consent was obtained from all patients for being included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}